Kymera therapeutics appoints noah goodman as chief business officer

Watertown, mass., april 09, 2025 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of noah goodman, m.b.a., as chief business officer. mr. goodman brings a wealth of diverse experience in the life sciences industry to kymera and will lead business development strategy and activities for the company.
NOAH Ratings Summary
NOAH Quant Ranking